Atea Pharmaceuticals, Inc. Common Stock
AVIRStock
$4.71+25.00%52W
Market Cap$388.93M
P/E—
Div yield—
Beta0.27
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)29.15%
Price vs S&P 500 (4W)8.44%
VGM Score65.15
Market Capitalization$388.93M
Earnings Surprise History
Q1 26-0.57est. -0.60
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.11
4.11
4.11
4.11
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AVIRAtea Pharmaceuticals, Inc. Common Stock | B | — | C | $4.71 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing antiviral therapies for serious viral infections. The company's lead candidate, bemnifosbuvir, is in development for COVID-19, and a combination of bemnifosbuvir and ruzasvir is being evaluated for Hepatitis C treatment.